|Bid||85.99 x 4900|
|Ask||86.00 x 100|
|Day's Range||85.91 - 86.05|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.42|
|Dividend & Yield||2.72 (3.17%)|
|1y Target Est||N/A|
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.
In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis.
In 1H17, Novartis’s (NVS) Gilenya reported revenues of around $1.6 billion, which reflected ~3% growth on a year-over-year (or YoY) basis.